Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
21,390,291
-
Share change
-
+3,406,072
-
Total reported value
-
$320,854,510
-
Put/Call ratio
-
75%
-
Price per share
-
$15.00
-
Number of holders
-
103
-
Value change
-
+$51,912,609
-
Number of buys
-
63
-
Number of sells
-
30
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2023
As of 31 Dec 2023,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
103 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,390,291 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., GREAT POINT PARTNERS LLC, MENORA MIVTACHIM HOLDINGS LTD., RTW INVESTMENTS, LP, BlackRock Inc., CREDIT SUISSE AG/, Harel Insurance Investments & Financial Services Ltd., Migdal Insurance & Financial Holdings Ltd., SILVERARC CAPITAL MANAGEMENT, LLC, and Wildcat Capital Management, LLC.
This page lists
103
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.